Found 27 results
Author [ Title(Desc)] Type Year
Filters: Author is Dally, L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
J. Kim, Dally, L., Ederer, F., Gaasterland, D., Van Veldhuisen, P., Blackwell, B., Sullivan, E., Prum, B., Shafranov, G., Beck, A., Spaeth, G., and Investigators, A. G. I. S., “The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations”, Ophthalmology, vol. 111, pp. 2109-2116, 2004.
B
W. Stevens, Kamali, A., Karita, E., Anzala, O., Sanders, E. J., Jaoko, W., Kaleebu, P., Mulenga, J., Dally, L., Fast, P., Gilmour, J., Farah, B., Birungi, J., Hughes, P., Manigart, O., Stevens, G., Yates, S., Thomson, H., ,, Stoll-Johnson, L., and Ketter, N., “Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials”, PLoS ONE, vol. 3, p. e2043, 2008.
C
A. Mariotto, Dally, L., Micheli, A., Canario, F., and Verdecchia, A., “Cancer prevalence in Italian regions with local cancer registries”, Tumori, vol. 85, pp. 400-7, 1999.
O. G Manyonyi, Jaoko, W., Wakasiaka, S., Bwayo, J., Achola, N. J., Schmidt, C., Bhatt, K., Ogutu, H., K’owino, D., Dally, L., Malogo, R., and Fast, P., “Challenges Experienced By the Clinical Team During The Conduct of HIV Vaccine Clinical Trials in Kenya”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
A. Vigano, Dally, L., Bricalli, D., Sala, N., Pirillo, M., Saresella, M., Trabattoni, D., Vella, S., Clerici, M., and Principi, N., “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection”, J Pediatric, vol. 135, pp. 675-82, 1999.
A. Vigano, Dally, L., Bricalli, D., Sala, N., Pirillo, M., Saresella, M., Trabattoni, D., Vella, S., Clerici, M., and Principi, N., “Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.”, J Pediatr, vol. 135, no. 6, pp. 675-82, 1999.
E. Karita, Anzala, O., Gazzard, B., Bergin, P., Nyombayire, J., Omosa, G., ,, Dally, L., Barin, B., Inoue, M., Hara, H., Hironaka, T., Shu, T., Hasegawa, M., Matano, T., Sayeed, E., Parks, C., Ackland, J., Fast, P., Gilmour, J., Cox, J., Lombardo, A., and Laufer, D., “Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers”, in HIVR4P (HIV Research for Prevention), Cape Town, South Africa, 2014.
A. Kamali, Karita, E., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E., Mwangome, M., Allen, S., Amornkul, P., Price, M., Stevens, G., Dally, L., Excler, J., and , “A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials”, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
D
M. Merli, Riggio, O., and Dally, L., “Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi).”, Hepatology, vol. 23, no. 5, pp. 1041-6, 1996.
I
N. Goonetilleke, Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., Pinheiro, S., Gillespie, G., Brown, D., Loach, V., Roberts, J., Guimar-Walker, A., Hayes, P., Loughran, K., Smith, C., DeBont, J., Verlinde, C., Vooijs, D., Schmidt, C., and McMichael, A. [..], “Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA-and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes”, J Virol, vol. 80, pp. 4717-4728, 2006.
L
A. Guimarães-Walker, Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., Moore, S., Goonetilleke, N., and Fast, P., “Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.”, Vaccine, vol. 26, no. 51, pp. 6671-7, 2008.
N
F. Menghini, Dally, L., Fazzini, P. F., Menotti, A., Prati, P. L., Rovelli, F., Antoniucci, D., and Seccareccia, F., “Normal behaviour of circulatory parameters during exercise. Reference values for heart rate and systemic blood pressure. The ECCIS Project data. Epidemiologia e Clinica della Cardiopatia Ischemica Silente.”, G Ital Cardiol, vol. 25, no. 8, pp. 967-75, 1995.
P
S. Vasan, Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D., and Gilmour, J., “Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine”, PLoS ONE, vol. 5, p. e8617, 2010.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Heald, A., Anklesaria, P., Dally, L., Boaz, M., Fast, P., and Schmidt, C., “A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
B. Peters, Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., Gray, K., Fast, P., Schmidt, C., Gilmour, J., Smith, C., Dally, L., Loughran, K., Farah, B., Tarragona, T., Hayes, P., McMichael, A., Hanke, T., and Bwayo, J., “Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
G. Omosa-Manyonyi, Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., ,, Gilmour, J., Cox, J., Fast, P., and Priddy, F., “A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults”, PLoS One, vol. 10, p. e0125954, 2015.
A. Guimarães-Walker, Mackie, N., McMichael, A., Weber, J., McCormack, S., Cebere, I., Kay, R., Hanke, T., Dally, L., Gibiansky, L., Legg, K., DeSouza, C., Hayes, P., Gilmour, J., and Fast, P., “Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection”, 2004.
A. L. Fontanet, Saba, J., Chandelying, V., Sakondhavat, C., Bhiraleus, P., Rugpao, S., Chongsomchai, C., Kiriwat, O., Tovanabutra, S., Dally, L., Lange, J. M., and Rojanapithayakorn, W., “Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial”, AIDS, vol. 12, pp. 1851-9, 1998.
A. L. Fontanet, Saba, J., Chandelying, V., Sakondhavat, C., Bhiraleus, P., Rugpao, S., Chongsomchai, C., Kiriwat, O., Tovanabutra, S., Dally, L., Lange, J. M., and Rojanapithayakorn, W., “Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial.”, AIDS, vol. 12, no. 14, pp. 1851-9, 1998.
S
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., “Safety and Immunogenicity of MVA.HIVA by 3 Different Routes”, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
J. W, FN, N., O, A., G, O. Manyonyi, J, B., A, N., F, B., K, B., H, O., S, W., L, M., W, W., J, O., M, O., J, I., J, N. - A., C, K., ,, Smith, C., Barin, B., Dally, L., ,, and Kaleebu, P., “Safety and Immunogenicity of Recombinant Low-Dosage HIV-1 A Vaccine Candidates Vectored by Plasmid pTHr DNA or Modified Vaccinia Virus Ankara (MVA) in Humans in East Africa”, Vaccine, vol. 26, pp. 2788-2795, 2008.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., “Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E., Graham, B., Koup, R., Bailer, R., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C., Bizimana, J., Tarragona-Fiol, T., Bergin, P., Hayes, P., Ho, M., Loughran, K., and Komaroff, W., “Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa”, PLoS ONE, vol. 5, p. e12873, 2010.
L. Van Damme, Niruthisard, S., Atisook, R., Boer, K., Dally, L., Laga, M., Lange, J. M., Karam, M., and Perriens, J. H., “Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection”, AIDS, vol. 12, pp. 433-7, 1998.
L. Van Damme, Niruthisard, S., Atisook, R., Boer, K., Dally, L., Laga, M., Lange, J. M., Karam, M., and Perriens, J. H., “Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection.”, AIDS, vol. 12, no. 4, pp. 433-7, 1998.